2011 Form 8-K Financial Statement
#000104746913000481 Filed on January 28, 2013
Income Statement
| Concept | 2011 | 2010 Q4 | 2010 Q3 |
|---|---|---|---|
| Revenue | $435.2K | $143.0K | $51.33K |
| YoY Change | -82.41% | -86.63% | 413.31% |
| Cost Of Revenue | $100.0K | $0.00 | $0.00 |
| YoY Change | -66.67% | -100.0% | |
| Gross Profit | $400.0K | $140.0K | $50.00K |
| YoY Change | -81.82% | -81.82% | 400.0% |
| Gross Profit Margin | 91.92% | 97.88% | 97.41% |
| Selling, General & Admin | $7.000M | $1.370M | $1.530M |
| YoY Change | 18.64% | -15.95% | 1.32% |
| % of Gross Profit | 1750.0% | 978.57% | 3060.0% |
| Research & Development | $44.18M | $11.90M | $9.716M |
| YoY Change | 11.27% | 218.31% | 188.31% |
| % of Gross Profit | 11045.57% | 8503.53% | 19432.18% |
| Depreciation & Amortization | $148.2K | $40.00K | $41.00K |
| YoY Change | -11.75% | 0.0% | 2.5% |
| % of Gross Profit | 37.06% | 28.57% | 82.0% |
| Operating Expenses | $44.18M | $11.90M | $9.716M |
| YoY Change | 11.27% | -53.5% | 97.88% |
| Operating Profit | -$43.78M | -$13.17M | -$11.24M |
| YoY Change | 16.74% | -46.97% | 129.39% |
| Interest Expense | $681.6K | -$350.0K | $172.0K |
| YoY Change | -0.95% | 191.67% | |
| % of Operating Profit | |||
| Other Income/Expense, Net | $240.0K | $0.00 | |
| YoY Change | |||
| Pretax Income | -$51.61M | -$13.27M | -$11.59M |
| YoY Change | 11.72% | -59.16% | 81.95% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$51.60M | -$13.27M | -$11.59M |
| YoY Change | 11.69% | -59.16% | 81.95% |
| Net Earnings / Revenue | -11857.71% | -9277.64% | -22578.95% |
| Basic Earnings Per Share | -$3.15 | ||
| Diluted Earnings Per Share | -$3.15 | -$6.668M | -$5.854M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 16.40M shares | 71.19M shares | |
| Diluted Shares Outstanding | 16.40M shares |
Balance Sheet
| Concept | 2011 | 2010 Q4 | 2010 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $57.20M | $38.20M | $35.50M |
| YoY Change | 49.74% | 27.76% | 168.94% |
| Cash & Equivalents | $57.20M | $38.16M | $35.53M |
| Short-Term Investments | |||
| Other Short-Term Assets | $800.0K | $2.500M | $1.200M |
| YoY Change | -68.0% | 66.67% | 20.0% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $0.00 | $0.00 | |
| Other Receivables | $0.00 | $0.00 | |
| Total Short-Term Assets | $58.00M | $40.63M | $36.70M |
| YoY Change | 42.86% | 29.38% | 158.45% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $900.0K | $635.8K | $600.0K |
| YoY Change | 50.0% | -9.17% | -14.29% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $3.400M | $3.400M | $3.300M |
| YoY Change | 0.0% | -5.56% | 3200.0% |
| Other Assets | $100.0K | $100.0K | $100.0K |
| YoY Change | 0.0% | -85.71% | -88.89% |
| Total Long-Term Assets | $4.400M | $4.142M | $4.100M |
| YoY Change | 4.76% | -17.17% | 127.78% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $58.00M | $40.63M | $36.70M |
| Total Long-Term Assets | $4.400M | $4.142M | $4.100M |
| Total Assets | $62.40M | $44.77M | $40.80M |
| YoY Change | 39.29% | 22.99% | 155.0% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $3.200M | $4.864M | $4.500M |
| YoY Change | -34.69% | 102.68% | 28.57% |
| Accrued Expenses | $4.100M | $2.200M | $2.600M |
| YoY Change | 86.36% | 46.67% | 116.67% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | $1.100M | |
| YoY Change | -100.0% | ||
| Total Short-Term Liabilities | $7.200M | $8.183M | $7.100M |
| YoY Change | -12.2% | 109.83% | 47.92% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $17.30M | $17.40M | $18.40M |
| YoY Change | -0.57% | 4.19% | |
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $17.30M | $17.40M | $18.40M |
| YoY Change | -0.57% | 4.19% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $7.200M | $8.183M | $7.100M |
| Total Long-Term Liabilities | $17.30M | $17.40M | $18.40M |
| Total Liabilities | $24.60M | $25.62M | $25.50M |
| YoY Change | -3.91% | 24.37% | 431.25% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$165.6M | ||
| YoY Change | |||
| Common Stock | |||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $37.80M | $19.15M | $15.30M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $62.40M | $44.77M | $40.80M |
| YoY Change | 39.29% | 22.99% | 155.0% |
Cashflow Statement
| Concept | 2011 | 2010 Q4 | 2010 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$51.60M | -$13.27M | -$11.59M |
| YoY Change | 11.69% | -59.16% | 81.95% |
| Depreciation, Depletion And Amortization | $148.2K | $40.00K | $41.00K |
| YoY Change | -11.75% | 0.0% | 2.5% |
| Cash From Operating Activities | -$47.87M | -$14.21M | -$10.85M |
| YoY Change | 19.38% | 131.43% | 191.67% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $719.9K | -$30.00K | -$10.00K |
| YoY Change | 1034.79% | 50.0% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cash From Investing Activities | -$720.0K | -$30.00K | -$10.00K |
| YoY Change | 1100.0% | 200.0% | |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $23.88M | ||
| YoY Change | -50.72% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 67.66M | 16.86M | 0.000 |
| YoY Change | 39.65% | -26.18% | -100.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -47.87M | -14.21M | -10.85M |
| Cash From Investing Activities | -720.0K | -30.00K | -10.00K |
| Cash From Financing Activities | 67.66M | 16.86M | 0.000 |
| Net Change In Cash | 19.07M | 2.620M | -10.86M |
| YoY Change | 130.04% | -84.3% | -251.04% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$47.87M | -$14.21M | -$10.85M |
| Capital Expenditures | $719.9K | -$30.00K | -$10.00K |
| Free Cash Flow | -$48.59M | -$14.18M | -$10.84M |
| YoY Change | 20.98% | 131.7% | 191.4% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2011Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
62379755 | USD |
| CY2011 | us-gaap |
Licenses Revenue
LicensesRevenue
|
100000 | USD |
| CY2010 | us-gaap |
Licenses Revenue
LicensesRevenue
|
115807 | USD |
| CY2010 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
51870 | USD |
| CY2011Q4 | us-gaap |
Common Stock Value Outstanding
CommonStockValueOutstanding
|
255054440 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
32442 | USD |
| CY2010 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2014 | USD |
| CY2011 | bpax |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
24062 | USD |
| CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1177683 | USD |
| CY2010 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
992757 | USD |
| CY2009 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1254503 | USD |
| CY2011 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1177683 | USD |
| CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
204980 | USD |
| CY2010 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
65529 | USD |
| CY2009 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
64103 | USD |
| CY2010 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
992757 | USD |
| CY2009 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1254503 | USD |
| CY2011 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
204980 | USD |
| CY2010 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
65529 | USD |
| CY2009 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
64103 | USD |
| CY2011 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-367502 | USD |
| CY2010 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-4583 | USD |
| CY2010 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
65807 | USD |
| CY2009 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-60739 | USD |
| CY2010 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
365332 | USD |
| CY2009 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
30263 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
134103 | USD |
| CY2010 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
3142078 | USD |
| CY2009 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
116389 | USD |
| CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
38155251 | USD |
| CY2008Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
11760920 | USD |
| CY2009 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1548535 | USD |
| CY2011 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="FONT-FAMILY: times"><font size="2"><b>1. DESCRIPTION OF BUSINESS</b></font></p> <p style="FONT-FAMILY: times"><font size="2">        BioSante Pharmaceuticals, Inc. (the Company) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. The Company's products, either approved or in human clinical development, include: (1) LibiGel, once daily transdermal testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD); (2) a once daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of hypogonadism, or testosterone deficiency in men, and licensed to Teva Pharmaceuticals USA, Inc. (Teva); (3) GVAX cancer vaccines, a portfolio of cancer vaccines, four of which have been granted FDA orphan drug designation, and are currently in 17 Phase I and Phase II clinical trials for the treatment of various cancers; (4) The Pill-Plus (triple component contraceptive), once daily use of various combinations of estrogens, progestogens and androgens in Phase II development; and (5) Elestrin, once daily transdermal estradiol (estrogen) gel approved by the FDA indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S. by Jazz Pharmaceuticals, Inc. (Jazz Pharmaceuticals), our licensee.</font></p> <p style="FONT-FAMILY: times"><font size="2">        The Company's lead product in development has been LibiGel for the treatment of FSD, specifically HSDD, in postmenopausal women, for which there is no FDA-approved pharmaceutical product. The Company continues to analyze the data from the two pivotal LibiGel Phase III efficacy trials first reported on December 14, 2011. Initial analysis of the efficacy data from these trials shows that the trials did not meet the co-primary or secondary endpoints. Although there were no statistical differences from placebo, results indicated that LibiGel performed as predicted based on previous experience with testosterone products for FSD. However, the placebo response in the two efficacy trials was overwhelming and unpredictable; and therefore, LibiGel's results were not shown to be statistically different from placebo. The LibiGel Phase III safety study, which completed enrollment in June 2011, continues and will continue during further analysis of the LibiGel efficacy data and until a final strategic decision has been made. It is the Company's objective to meet with the FDA to determine the best path forward, and to make a decision during the second quarter of 2012 whether to continue the LibiGel Phase III safety study.</font></p> <p style="FONT-FAMILY: times"><font size="2">        The Company's corporate strategy always has included product development of high value medically-needed pharmaceutical products. In light of recently announced top-line results from the Company's two pivotal LibiGel Phase III efficacy trials, the Company is assessing its corporate strategy. The Company is determining LibiGel's path forward and potential alternative strategies to utilize the continuing LibiGel Phase III cardiovascular events and breast cancer safety study. The Company also has expanded its efforts to explore new product development projects through in-licensing and mergers and acquisitions. In addition, a full review of the Company's GVAX cancer vaccine portfolio is underway.</font></p> <p style="FONT-FAMILY: times"><font size="2">        On January 31, 2012, the Company received a notice from the Listing Qualifications Department of The NASDAQ Stock Market indicating that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share required for continued inclusion on The NASDAQ Global Market under NASDAQ Listing Rule 5450(a)(1). The notification letter stated that pursuant to NASDAQ Listing Rule 5810(c)(3)(A), the Company will be afforded 180 calendar days, or until July 30, 2012, to regain compliance with the minimum bid price requirement. In order to regain compliance, shares of the Company's common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by July 30, 2012, the Company may transfer its common stock listing to The NASDAQ Capital Market and be eligible for an additional 180-day grace period if the Company meets the market value of publicly held shares requirement for continued listing and all other initial inclusion requirements for listing on The NASDAQ Capital Market, other than the minimum bid price requirement. In order to be afforded the additional 180-day compliance period, the Company also would need to provide NASDAQ written notice of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company does not indicate its intent to cure the deficiency or if it does not appear to NASDAQ that it is possible for the Company to cure the deficiency, the Company will not be eligible for the second 180-day grace period and its common stock will be subject to delisting, which delisting determination the Company may appeal to a hearings panel at that time.</font></p> | |
| CY2011 | dei |
Entity Registrant Name
EntityRegistrantName
|
BIOSANTE PHARMACEUTICALS INC | |
| CY2011 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001023024 | |
| CY2011 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
44961137 | USD |
| CY2011 | bpax |
Stock Issued During Period Value Common Shares And Warrants
StockIssuedDuringPeriodValueCommonSharesAndWarrants
|
23876370 | USD |
| CY2010 | bpax |
Stock Issued During Period Value Common Shares And Warrants
StockIssuedDuringPeriodValueCommonSharesAndWarrants
|
48452644 | USD |
| CY2011 | dei |
Document Type
DocumentType
|
8-K | |
| CY2011 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2011-12-31 | |
| CY2011 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2011 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
335160 | USD |
| CY2009 | bpax |
Stock Issued During Period Value Common Shares And Warrants
StockIssuedDuringPeriodValueCommonSharesAndWarrants
|
11352751 | USD |
| CY2011 | bpax |
Number Of Vaccines Granted With Fda Orphan Drug Designation
NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation
|
4 | vaccine |
| CY2009 | us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
3026334 | USD |
| CY2010 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
3075 | USD |
| CY2011 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
719925 | USD |
| CY2009 | us-gaap |
Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
|
36800043 | USD |
| CY2009 | bpax |
Adjustments To Additional Paid In Capital Credit Equity Financing Facility
AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility
|
60343 | USD |
| CY2010 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
2306560 | USD |
| CY2009 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
1141665 | USD |
| CY2011 | us-gaap |
Revenues
Revenues
|
435160 | USD |
| CY2010 | us-gaap |
Revenues
Revenues
|
2474237 | USD |
| CY2009 | us-gaap |
Revenues
Revenues
|
1258054 | USD |
| CY2010 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
63441 | USD |
| CY2009 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
165724 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-719925 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-60366 | USD |
| CY2011 | bpax |
Number Of Phase I And Phase Ii Clinical Trials
NumberOfPhaseIAndPhaseIIClinicalTrials
|
17 | item |
| CY2009 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
2860610 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
63969813 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
4095269 | USD |
| CY2011 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
44182260 | USD |
| CY2010 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
39705502 | USD |
| CY2009 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
13680573 | USD |
| CY2011 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6981490 | USD |
| CY2010 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5940360 | USD |
| CY2009 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5373945 | USD |
| CY2009 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
9000000 | USD |
| CY2009 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-2431252 | USD |
| CY2009 | us-gaap |
Cash Acquired From Acquisition
CashAcquiredFromAcquisition
|
24746346 | USD |
| CY2011 | bpax |
Repayments Of Short Term Convertible Debt
RepaymentsOfShortTermConvertibleDebt
|
1234000 | USD |
| CY2011 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
32442 | USD |
| CY2010 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2014 | USD |
| CY2011 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
24062 | USD |
| CY2011 | bpax |
Proceeds From Issuance Of Common Stock By Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering
|
44961137 | USD |
| CY2011 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
23876370 | USD |
| CY2010 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
48452644 | USD |
| CY2009 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
11352751 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
67660011 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
48454658 | USD |
| CY2009 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
33667845 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
19069983 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
8296786 | USD |
| CY2009 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
18097545 | USD |
| CY2011 | us-gaap |
Interest Paid
InterestPaid
|
688000 | USD |
| CY2010 | us-gaap |
Interest Paid
InterestPaid
|
688000 | USD |
| CY2011 | bpax |
Number Of New Libi Gel Phase Iii Efficacy Trials
NumberOfNewLibiGelPhaseIIIEfficacyTrials
|
2 | item |
| CY2012Q1 | bpax |
Number Of Consecutive Business Days For Which Common Stock Bid Price Is Below Minimum Requirement
NumberOfConsecutiveBusinessDaysForWhichCommonStockBidPriceIsBelowMinimumRequirement
|
P30D | |
| CY2012Q1 | bpax |
Number Of Days Afforded To Regain Complaince With Minimum Bid Price Requirement
NumberOfDaysAffordedToRegainComplainceWithMinimumBidPriceRequirement
|
P180D | |
| CY2012Q1 | bpax |
Additional Grace Period To Regain Complaince If Stock Listing Is Transferred To Nasdaq Capital Market
AdditionalGracePeriodToRegainComplainceIfStockListingIsTransferredToNASDAQCapitalMarket
|
P180D | |
| CY2009 | us-gaap |
Interest Paid
InterestPaid
|
248388 | USD |
| CY2010 | bpax |
Noncash Investment
NoncashInvestment
|
65807 | USD |
| CY2011 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<ul> <li style="list-style: none"> <p style="FONT-FAMILY: times"><font size="2"><i>Reclassifications</i></font></p></li></ul> <p style="FONT-FAMILY: times"><font size="2">        Certain amounts in the 2010 and 2009 financial statements have been reclassified to conform to their presentation in the 2011 financial statements. Specifically, in the statement of cash flows, the changes related to Accounts receivable in the amounts of $64,645 and $285,838 for the years ended December 31, 2010 and 2009, respectively, have been combined into the Prepaid expenses and other assets line item within the net cash used in operating activities section.</font></p> | |
| CY2011 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | item |
| CY2011 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | item |
| CY2010 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
64645 | USD |
| CY2009 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
285838 | USD |
| CY2011Q4 | bpax |
Fdic Insured Account Percentage Of Balance Insured
FDICInsuredAccountPercentageOfBalanceInsured
|
1.00 | pure |
| CY2010Q4 | bpax |
Fdic Insured Account Percentage Of Balance Insured
FDICInsuredAccountPercentageOfBalanceInsured
|
1.00 | pure |
| CY2010Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
3405807 | USD |
| CY2010 | us-gaap |
Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
|
286000 | USD |
| CY2011Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1287453 | USD |
| CY2010Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1081623 | USD |
| CY2011Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
426089 | USD |
| CY2010Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
635776 | USD |
| CY2011Q4 | bpax |
Deferred Tax Assets Deferred Financing Costs
DeferredTaxAssetsDeferredFinancingCosts
|
7010462 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
8266610 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2754981 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
448140 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
86545275 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
86545275 | USD |
| CY2010Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
46071206 | USD |
| CY2010Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
4452360 | USD |
| CY2010Q4 | bpax |
Deferred Tax Assets Deferred Financing Costs
DeferredTaxAssetsDeferredFinancingCosts
|
7001619 | USD |
| CY2010Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
5796148 | USD |
| CY2010Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2310405 | USD |
| CY2010Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
25955 | USD |
| CY2010Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
65657693 | USD |
| CY2010Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
65657693 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2011Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
169456000 | USD |
| CY2011Q4 | bpax |
Percentage Of Provision Of Valuation Allowance To Reduce Deferred Tax Assets
PercentageOfProvisionOfValuationAllowanceToReduceDeferredTaxAssets
|
1.00 | pure |
| CY2011 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.345 | pure |
| CY2011 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-17804934 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-15937695 | USD |
| CY2009 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-16397080 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-1677276 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-1501377 | USD |
| CY2009 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-1544652 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
|
-1537863 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
|
-966941 | USD |
| CY2009 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
|
-515235 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
132491 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
133932 | USD |
| CY2009 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
17718 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
20887582 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
18272081 | USD |
| CY2009 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
18439249 | USD |
| CY2011 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2011Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
236747 | USD |
| CY2011Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
248632 | USD |
| CY2011Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
41718 | USD |
| CY2011 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
424294 | USD |
| CY2010 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
338588 | USD |
| CY2009 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
325093 | USD |
| CY2011 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
211494 | USD |
| CY2010 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
179349 | USD |
| CY2009 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
117969 | USD |
| CY2010Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2469879 | USD |
| CY2010Q4 | us-gaap |
Assets Current
AssetsCurrent
|
40625130 | USD |
| CY2010Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
99937 | USD |
| CY2010Q4 | us-gaap |
Assets
Assets
|
44766650 | USD |
| CY2010Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4864217 | USD |
| CY2010Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
526022 | USD |
| CY2010Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1681956 | USD |
| CY2010Q4 | us-gaap |
Senior Notes Current
SeniorNotesCurrent
|
1111132 | USD |
| CY2010Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
8183327 | USD |
| CY2010Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
17436201 | USD |
| CY2010Q4 | us-gaap |
Liabilities
Liabilities
|
25619528 | USD |
| CY2010Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-165630644 | USD |
| CY2010Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
44766650 | USD |
| CY2009 | bpax |
Excess Consideration Paid Over Fair Value
ExcessConsiderationPaidOverFairValue
|
20192194 | USD |
| CY2011 | us-gaap |
License Costs
LicenseCosts
|
50000 | USD |
| CY2010 | us-gaap |
License Costs
LicenseCosts
|
268750 | USD |
| CY2009 | us-gaap |
License Costs
LicenseCosts
|
299616 | USD |
| CY2011 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
148240 | USD |
| CY2010 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
167986 | USD |
| CY2009 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
137280 | USD |
| CY2011 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
51361990 | USD |
| CY2010 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
46082598 | USD |
| CY2009 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
48683608 | USD |
| CY2011 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-23427 | USD |
| CY2010 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-1870916 | USD |
| CY2009 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
33163 | USD |
| CY2011 | us-gaap |
Interest Expense
InterestExpense
|
681573 | USD |
| CY2010 | us-gaap |
Interest Expense
InterestExpense
|
688083 | USD |
| CY2009 | us-gaap |
Interest Expense
InterestExpense
|
147025 | USD |
| CY2011 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
15000 | USD |
| CY2010 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
244479 | USD |
| CY2011 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
8326 | USD |
| CY2010 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
12665 | USD |
| CY2009 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
11648 | USD |
| CY2011 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-51608504 | USD |
| CY2010 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-46196216 | USD |
| CY2009 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-47527768 | USD |
| CY2011 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.15 | |
| CY2010 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-4.21 | |
| CY2009 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-8.40 | |
| CY2011 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.15 | |
| CY2010 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-4.21 | |
| CY2009 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-8.40 | |
| CY2011 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
16397618 | shares |
| CY2010 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
10985291 | shares |
| CY2009 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
5658608 | shares |
| CY2011 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
16397618 | shares |
| CY2010 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
10985291 | shares |
| CY2009 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
5658608 | shares |
| CY2011 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-47870103 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-40097506 | USD |
| CY2009 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-18430910 | USD |
| CY2009Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29858465 | USD |
| CY2009 | us-gaap |
Stock Issued1
StockIssued1
|
36800043 | USD |
| CY2008Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13826419 | USD |
| CY2009Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
15830394 | USD |
| CY2010Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
19147122 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
37815292 | USD |
| CY2009 | us-gaap |
Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
|
18487298 | USD |
| CY2009 | us-gaap |
Noncash Or Part Noncash Acquisition Investments Acquired1
NoncashOrPartNoncashAcquisitionInvestmentsAcquired1
|
3486000 | USD |
| CY2009 | us-gaap |
Noncash Or Part Noncash Acquisition Other Assets Acquired1
NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1
|
293658 | USD |
| CY2011 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
21405 | USD |
| CY2011Q4 | bpax |
Number Of Stockholder Approved Equity Based Compensation Plans
NumberOfStockholderApprovedEquityBasedCompensationPlans
|
2 | item |
| CY2011 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1177683 | USD |
| CY2010 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
992757 | USD |
| CY2009 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1254503 | USD |
| CY2011Q1 | us-gaap |
Revenues
Revenues
|
57000 | USD |
| CY2011Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14864420 | USD |
| CY2011Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1593557 | USD |
| CY2011Q1 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
| CY2011Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-16442921 | USD |
| CY2011Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-17250676 | USD |
| CY2011Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.20 | |
| CY2011Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.96 | |
| CY2011Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.72 | |
| CY2011Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.36 | |
| CY2011Q2 | us-gaap |
Revenues
Revenues
|
81003 | USD |
| CY2011Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11116323 | USD |
| CY2011Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1989103 | USD |
| CY2011Q2 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
| CY2011Q4 | us-gaap |
Revenues
Revenues
|
114373 | USD |
| CY2011Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6701465 | USD |
| CY2011Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1723562 | USD |
| CY2011Q4 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
| CY2011Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8340710 | USD |
| CY2011Q4 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-6648906 | USD |
| CY2010Q1 | us-gaap |
Revenues
Revenues
|
2279874 | USD |
| CY2010Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9426870 | USD |
| CY2011Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13064942 | USD |
| CY2011Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14975231 | USD |
| CY2011Q3 | us-gaap |
Revenues
Revenues
|
182784 | USD |
| CY2011Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11500053 | USD |
| CY2011Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1675268 | USD |
| CY2011Q3 | us-gaap |
License Costs
LicenseCosts
|
50000 | USD |
| CY2011Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13028207 | USD |
| CY2011Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-12733691 | USD |
| CY2010Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1498252 | USD |
| CY2010Q1 | us-gaap |
License Costs
LicenseCosts
|
268750 | USD |
| CY2010Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8959419 | USD |
| CY2010Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10540419 | USD |
| CY2010Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.14 | |
| CY2010Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8657606 | USD |
| CY2010Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1540200 | USD |
| CY2010Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-10240352 | USD |
| CY2010Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10794351 | USD |
| CY2010Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.02 | |
| CY2010Q3 | us-gaap |
Revenues
Revenues
|
51331 | USD |
| CY2010Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9716091 | USD |
| CY2010Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1534417 | USD |
| CY2010Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11240177 | USD |
| CY2010Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-11589711 | USD |
| CY2010Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.96 | |
| CY2010Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.08 | |
| CY2010Q4 | us-gaap |
Revenues
Revenues
|
143032 | USD |
| CY2010Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11904935 | USD |
| CY2010Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1367491 | USD |
| CY2010Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13168413 | USD |
| CY2010Q4 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-13271735 | USD |
| CY2010Q4 | us-gaap |
Common Stock Value Outstanding
CommonStockValueOutstanding
|
184777766 | USD |
| CY2010Q2 | us-gaap |
Revenues
Revenues
|
0 | USD |
| CY2010Q2 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
| CY2010Q3 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
| CY2010Q4 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
